ğŸ’¬ Discussion & Interpretation
ğŸ§¬ Key Findings
Asymmetric Distribution: Synonymous mutations were not evenly distributed across gene regions, suggesting functional or structural constraints in mutation tolerance.

Impact on Treatment Response: Higher synonymous mutation burden was associated with significantly lower Complete Remission rates (OR â‰ˆ 0.60, p â‰ˆ 0.04), especially when stratified by ELN 2017 classification.

No Survival Link: No significant association was found with Overall Survival, indicating that synonymous mutations may affect early treatment response rather than long-term survival.

Mutation Hotspots: Clusters were identified in key genes like:

NOTCH1 â€“ signaling and differentiation

U2AF2 â€“ RNA splicing machinery

FLT3 â€“ tyrosine kinase signaling

âš™ï¸ Potential Mechanisms
Although â€œsilentâ€ at the protein level, synonymous mutations may influence:

âœ… Splicing regulation (exon skipping, splice site disruption)

âœ… mRNA stability and translational kinetics

âœ… Cotranslational folding and post-translational modification sites

âœ… Non-coding RNA binding (e.g., miRNA targeting)

For example:

The NOTCH1 mutation chr9:139395259 is located in an ankyrin repeat domain near known phosphorylation sites, which could alter protein interactions or stability.

âš ï¸ Limitations
Small cohort size limits statistical power.

No independent validation cohort available.

Functional validation (e.g., splicing assays) was not performed.

Rare variant frequency restricted in-depth per-mutation analysis.

ğŸš€ Future Directions
ğŸ”¬ Larger multi-omics cohorts with RNA-seq to assess splicing impacts.

ğŸ§ª Functional studies using minigene reporters or CRISPR editing.

ğŸ“Š Integration with proteomic data to assess protein-level effects.

ğŸ¥ Clinical translation into risk stratification tools.

âœ… Conclusion
This study suggests that synonymous mutations are not biologically silent in AML and may collectively influence therapeutic response. Their inclusion in genomic profiling could refine risk prediction and personalize treatment strategies in AML precision oncology.
